Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · IEX Real-Time Price · USD
50.55
-1.31 (-2.53%)
At close: Apr 16, 2024, 4:00 PM
49.57
-0.98 (-1.94%)
After-hours: Apr 16, 2024, 5:35 PM EDT

Janux Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019
Revenue
8.088.613.6400
Revenue Growth (YoY)
-6.14%136.79%---
Gross Profit
8.088.613.6400
Selling, General & Admin
26.1422.2610.331.80.77
Research & Development
54.9253.4426.243.043
Operating Expenses
81.0675.736.574.843.77
Operating Income
-72.98-67.09-32.93-4.84-3.77
Interest Expense / Income
0000.210.23
Other Expense / Income
-14.69-4.03-0.261.74-
Pretax Income
-58.29-63.06-32.67-6.78-4
Net Income
-58.29-63.06-32.67-6.78-4
Shares Outstanding (Basic)
44412411
Shares Outstanding (Diluted)
44412411
Shares Change
6.14%76.24%2471.20%36.71%-
EPS (Basic)
-1.32-1.52-1.39-7.41-5.98
EPS (Diluted)
-1.32-1.52-1.39-7.41-5.98
Free Cash Flow
-52.43-49.37-18.46-4.37-3.83
Free Cash Flow Per Share
-1.19-1.19-0.78-4.77-5.72
Gross Margin
100.00%100.00%100.00%--
Operating Margin
-902.87%-779.04%-905.39%--
Profit Margin
-721.18%-732.22%-898.32%--
Free Cash Flow Margin
-648.58%-573.24%-507.51%--
EBITDA
-56.34-62.22-32.56-6.57-3.77
EBITDA Margin
-696.99%-722.46%-895.22%--
Depreciation & Amortization
1.960.840.110.010.01
EBIT
-58.29-63.06-32.67-6.58-3.77
EBIT Margin
-721.18%-732.22%-898.32%--
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).